Insiders who reported open-market trades in the last 12 months at the companies David Young files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Russell Skibsted - $42K in PCSA purchases and sales in the last 12 months
George K. Ng - $39K in PCSA purchases and sales in the last 12 months
Wendy Guy - $33K in PCSA purchases and sales in the last 12 months
Patrick Lin - $28K in PCSA purchases and sales in the last 12 months
Sian Bigora - $21K in PCSA purchases and sales in the last 12 months
Khoso Baluch - $6K in PCSA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
David Young is a corporate insider, tracked as Pres. Research & Development of Processa Pharmaceuticals, Inc. (PCSA). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did David Young last file a Form 4?
The most recent primary Form 4 on record is dated 1 July 2026, one of 10 filings going back to 2025.
Has David Young been buying or selling stock?
Recorded transactions: 7 open-market purchases ($32K) and 0 open-market sales across all tracked filings.
David Young is Pres. Research & Development of Processa Pharmaceuticals, Inc. (PCSA). 10 SEC Form 4 filings on record going back to 2025, most recently on 1 July 2026. Most recent open-market trade: bought $5K of PCSA on 1 July 2026. Lifetime open-market purchases: $32K.
Recent transactions
8
The latest 8 SEC Form 4 transactions reported by David Young.
InsiderAlpha's records for David Young go back to 2025: 10 primary Form 4 filings, an average of 5.0 per year. The typical open-market purchase is $5K (7 buys totaling $32K). The largest single buy on record is $5K of PCSA in 2026. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
